Mingzhun Medical Secures Over Tens of Millions in Angel Funding to Pioneer Biomedical Optical Imaging Applications

VCBeat has learned that Shenzhen INTOTO BIOTECH Co., Ltd. (hereinafter referred to as “INTOTO BIOTECH”) held a signing ceremony for its first round of financing on the morning of May 24, 2023, announcing the completion of an angel round led by Suzhou Bilingxing Venture Capital, with the financing amount exceeding RMB 10 million.

INTOTO BIOTECH is an innovative medical device company whose core mission is to pioneer the first clinical applications of cutting-edge optical microscopy imaging technologies. The INTOTO team possesses extensive expertise in bio-optical technologies and tissue imaging applications. By leveraging breakthrough novel optical microscopy imaging techniques, the company is developing an internationally leading new digital pathology technology platform and building a portfolio of high-end, innovative histopathological imaging instruments. INTOTO BIOTECH will establish its presence in the fields of clinical medical devices, high-throughput drug screening, and scientific research instruments, aiming to become a leading enterprise in China and a world-class player in the global optical microscopy instrumentation industry.

He Jiaye, CEO of INTOTO BIOTECH

Zheng Hairong, Vice President of the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, and Director of the National Innovation Center, was invited to attend the signing ceremony. At the event, he stated that INTOTO BIOTECH is one of the most promising high-quality enterprises successfully incubated by the National Innovation Center. As a national-level manufacturing innovation center, the National Innovation Center will continue to provide technological and resource support to INTOTO BIOTECH, facilitating breakthroughs and growth in domestically produced high-end medical devices.

Zheng Hairong, Deputy Director of the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, and Director of the National Innovation Center

Li Zhe, Partner at Proxima Ventures, pointed out that Proxima Ventures continues to focus on the application of global innovative technologies in the healthcare sector. INTOTO BIOTECH represents a highly valued interdisciplinary innovative application for Proxima Ventures. Its team possesses composite expertise across multiple disciplines, pioneering the clinical application of world-leading biomedical optical imaging technology in histopathological diagnosis to create globally leading innovative medical devices. Proxima Ventures remains firmly optimistic about INTOTO BIOTECH’s strategic positioning and breakthrough progress in the medical device sector, and will provide ample clinical and industrial resources to offer comprehensive support and empowerment.

Li Zhe, Partner at Proxima Ventures

In the future, INTOTO BIOTECH will continue to unlock the potential of technological innovation and pursue excellence, making significant contributions to the advancement of global healthcare. We are confident that in the near future, INTOTO BIOTECH will emerge as a leading enterprise in the global healthcare sector, driving the industry to new heights.